Recent advance of ATP citrate lyase inhibitors for the treatment of cancer and related diseases

Authors：Liang, Jian-Jia; Zhou, Xiang-Feng; Long, Hui; Li, Chun-Yun; Wei, Jing; Yu, Xiao-Qin; Guo, Zhi-Yong; Zhou, Yi-Qing; Deng, Zhang-Shuang^*

Source：Bioorganic Chemistry, 2024, 142: 106933.

DOI：10.1016/j.bioorg.2023.106933

• ACLY
• Inhibitors
• Lipidic metabolism
• Cancer
• SAR studies

ATP citrate lyase (ACLY), a strategic metabolic enzyme that catalyzes the glycolytic to lipidic metabolism, has gained increasing attention as an attractive therapeutic target for hyperlipidemia, cancers and other human diseases. Despite of continual research efforts, targeting ACLY has been very challenging. In this field, most reported ACLY inhibitors are "substrate-like" analogues, which occupied with the same active pockets. Besides, some ACLY inhibitors have been disclosed through biochemical screening or high throughput virtual screening. In this review, we briefly summarized the cancer-related functions and the recent advance of ACLY inhibitors with a particular focus on the SAR studies and their modes of action. We hope to provide a timely and updated overview of ACLY and the discovery of new ACLY inhibitors.

• Institution
  中国科学院